Restricted accessOtherFirst published online 2012-9
Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective,randomized,controlled multicenter clinical trial
Both intravitreal pegaptanib with laser therapy and intravitreal bevacizumab monotherapy have been found to be more efficacious than laser therapy alone in prospective, randomized, controlled clinical trials.
Results
The use of pegaptanib with laser therapy was efficacious in 91.2% compared with 69.0% in controls. The use of bevacizumab monotherapy was efficacious in 95.7% compared with 78.1% in controls.
Conclusions
The use of anti–vascular endothelial growth factor therapy for retinopathy of prematurity has been shown to be efficacious, without toxicity reported to date; however, the best drug and dose which allows greatest efficacy with fewest recurrences and without toxicity must be determined.
AutrataR., KejcirovaI., SenkovaK., HolousovaM., DolezelZ., BorekI.. Efficacy of intravitreal pegaptanib as adjunctive treatment for stage 3+ retinopathy of prematurity in zone I and posterior zone II.Eur J Ophthalmol2012; 22.
2.
Mintz-HittnerH.A., KennedyK.A., ChuangA.Z.; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.N Engl J Med2011; 364: 603–15.
3.
HuJ., BlairM.P., ShapiroM.J., LichtensteinS.J., GalassoJ.M., KapurR.. Reactivation of retinopathy of prematurity after bevacizumab Injection.Arch Ophthalmol Epub2012 Apr 9.
4.
HartnettM.E.. Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an American Ophthalmological Society thesis).Trans Am Ophthalmol Soc2010; 108: 96–119.
5.
SatoT., WadaK., ArahoriH.Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.Am J Ophthalmol2012; 153: 327–33.
